Definition & Classification

Evans syndrome (ES) is a rare, life-threatening autoimmune cytopenia defined by the concurrent or sequential occurrence of two or more immune-mediated blood cytopenias, most commonly:

• Immune thrombocytopenia (ITP; IgG-mediated platelet destruction),
• Autoimmune hemolytic anemia (AIHA; IgG/IgM-mediated RBC destruction), and/or
• Immune neutropenia (IgG- or complement-mediated neutrophil destruction).

The British Committee for Standards in Haematology (BCSH, 2023) and American Society of Hematology (ASH, 2023) emphasize that ES is a diagnosis of exclusion, requiring rigorous evaluation to rule out mimics—especially underlying lymphoproliferative disorders (LPDs), inborn errors of immunity (IEIs), and complement-mediated conditions.

Classification:

• Primary (idiopathic) ES: No identifiable cause; ~50–60% of cases.
• Secondary ES: Associated with:
  • Lymphoproliferative disorders: Chronic lymphocytic leukemia (CLL), marginal zone lymphoma, hairy cell leukemia (~30% of adult cases).
  • Autoimmune disorders: Systemic lupus erythematosus (SLE), common variable immunodeficiency (CVID), IPEX-like syndromes.
  • Inborn errors of immunity (IEIs): CTLA-4 haploinsufficiency, LRBA deficiency, ALPS (autoimmune lymphoproliferative syndrome).
  • Post-viral or post-vaccinal (rare; e.g., EBV, CMV, SARS-CoV-2).

Key diagnostic criterion (ASH 2023): Co-occurrence of AIHA + ITP or AIHA + neutropenia or ITP + neutropenia—either simultaneously or with a remission–relapse pattern over time.

Epidemiology & Clinical Course

• Incidence: ~1.4 cases per million/year (pediatric: 25% of cases present <2 years old).
• Bimodal age distribution: Children (peak 1–6 years) and adults (>40 years).
• Poor prognostic factors:
  • Age >60, severe cytopenias (Hb <7 g/dL, platelets <10 × 10⁹/L, ANC <0.5 × 10⁹/L),
  • Need for multiple lines of therapy,
  • Presence of LPD/IEI.
• 5-year overall survival: ~80% in children; ~60–70% in adults (per Blood Adv 2022 cohort study, n=312).

Clinical Manifestations

Symptoms reflect the degree and rapidity of cytopenia development:

Systemic features: Lymphadenopathy (25–40%), hepatosplenomegaly (30–50%; suggests underlying LPD or ALPS), fever (sign of infection or disease flares).

Diagnostic Workup: Stepwise Approach

Per BCSH 2023 & ASH guidelines (2023)

1. Confirm Cytopenias & Hemolysis

• CBC + peripheral smear: Look for:
  • polychromasia, schistocytes (rule out TMA),
  • agglutination (cold AIHA),
  • giant platelets (suggestive of MYH9 disorders).
• Hemolysis panel: LDH, indirect bilirubin, haptoglobin, reticulocyte count, urine hemoglobin.
• DAT (Coombs test):
  • IgG±C3d positivity = warm AIHA;
  • C3d-only = cold AIHA or complement-mediated;
  • DAT-negative AIHA occurs in ~5–10% of cases—diagnosis is clinical + exclusionary.

2. Exclude Mimics & Identify Secondary Causes

• Infection screen: HIV, HCV, EBV, CMV, Mycoplasma, Bartonella.
• Autoimmune workup:
  • ANA, anti-dsDNA, complement (C3/C4) for SLE;
  • Serum IgG/IgA/IgM, specific antibodies (pneumococcal, tetanus), lymphocyte subsets (CD19+, CD20+, CD21lo, CD27+ memory B cells) for CVID/IEI.
• Genetic testing:
  • CTLA4, LRBA, FAS, FASL, CASP10 (for ALPS/IEI) in children or familial cases;
  • DNASE1L3, MYH9 if atypical features.
• Malignancy evaluation:
  • Flow cytometry on peripheral blood/bone marrow for clonal B-cells (CD5+, CD23+ → CLL);
  • Bone marrow biopsy (if cytopenias severe, dysplastic features, or persistent cytopenias beyond 6 months).
  • CT/PET-CT if lymphadenopathy/hepatosplenomegaly present.

Red flags for secondary ES:

• Age >40 with new-onset ES,
• Lymphocytosis (>5 × 10⁹/L B-cells),
• Splenomegaly + cytopenias,
• Recurrent infections + hypogammaglobulinemia.

Treatment: Risk-Adapted, Goal-Directed Therapy

Based on ASH 2023 guidelines, real-world evidence (REPAIR-ES registry), and meta-analyses (Haematologica 2023)

First-Line Therapies

1. Corticosteroids:
   • Prednisone 1 mg/kg/day (max 60 mg) for 2–4 weeks, then taper over 4–8 weeks.
   • Limitations: Only ~50% achieve durable remission; long-term toxicity (osteoporosis, diabetes, infections) limits use.
2. IVIG ± Anti-D:
   • IVIG 1 g/kg/day × 1–2 days for rapid platelet/RBC support.
   • Anti-D (RhoGAM) only in RhD+ patients with intact spleen; caution in volume overload and hemolysis.

Second-Line Therapies

• Rituximab (anti-CD20 monoclonal antibody):
  • 375 mg/m² IV weekly × 4 doses or 1 g IV × 2 doses (2 weeks apart).
  • Response rate: ~50–60% in ES (vs 30% in isolated ITP); median duration 6–12 months.
  • Advantage: Fewer infections vs alkylating agents; but risk of hypogammaglobulinemia with repeated courses.
• Mycophenolate Mofetil (MMF):
  • Dose: 1–2 g/day in divided doses; monitor levels if available.
  • Better safety profile for maintenance, especially in children. Response in ~40% after rituximab failure (Br J Haematol 2022).
• Sirolimus:
  • Emerging as preferred mTOR inhibitor over everolimus (less metabolic toxicity).
  • Dose: Target trough 5–8 ng/mL.
  • High remission rates (67%) in IEI-associated ES (Blood Adv 2021; n=48).

Third-Line & Beyond

• Splenectomy:
  • Consider if refractory to ≥2 lines; response rate ~50–65%.
  • Caveats: Lifelong vaccination (pneumococcus, meningococcus, H. influenzae), antibiotic prophylaxis (penicillin V).
  • Avoid in ALPS/IEI (high lymphoma risk).
• Immunomodulators:
  • Rituximab + dexamethasone (RD regimen): Used off-label; higher response than rituximab monotherapy.
  • Bortezomib: Proteasome inhibitor—case reports show efficacy in refractory ES.
• Emerging Agents:
  • Fostamatinib (SYK inhibitor): Approved for chronic ITP; ES case series (n=12) show platelet responses in 58% (Am J Hematol 2023).
  • Luspatercept: For refractory AIHA with ring sideroblasts—off-label use under investigation.
  • CTLA-4-Ig (abatacept): Highly effective in CTLA-4/LRBA deficiency (J Allergy Clin Immunol 2020).

Supportive Care

• Transfuse RBCs/platelets only for active bleeding or severe symptoms (Hb <7–8 g/dL; platelets <10 × 10⁹/L + bleeding).
• Avoid splenotoxic drugs (e.g., methotrexate if planning splenectomy).
• Vaccinate against encapsulated organisms pre-splenectomy.

Prognosis & Monitoring

• Relapse rate: ~50% within 2 years; second-line therapies often required.
• Long-term monitoring:
  • Monthly CBC for 3 months post-treatment, then quarterly if stable.
  • Annual immunoglobulin levels (especially after rituximab).
  • Suspicion for LPD: periodic lymph node US/PET-CT in high-risk patients.

Key Clinical Take-Home Points

1. ES is not a single disease—it’s a phenotype with diverse etiologies requiring tailored workup.
2. Rule out IEI and LPD in adults; consider genetic testing in children with early-onset or familial cytopenias.
3. Rituximab + sirolimus/MMF are preferred second-line over splenectomy in many centers due to better safety.
4. Avoid aggressive immunosuppression upfront—risk of opportunistic infections is high.
5. Multidisciplinary management (hematology, immunology, genetics) improves outcomes.

References

• BCSH Guidelines (2023). Br J Haematol. 201(2):169–182.
• Ashrafi M et al. (2023). Evans syndrome: A population-based study of 312 cases. Blood Adv. 7(15):3894–3904.
• Zhang J et al. (2022). Second-line therapies for Evans syndrome: A meta-analysis. Haematologica. 107(5):1168–1177.
• O’Toole M et al. (2023). Fostamatinib in refractory immune cytopenias. Am J Hematol. 98(4):521–528.
• DUKE IEI Registry (2024). Abatacept in CTLA-4 haploinsufficiency. J Allergy Clin Immunol (in press).